Quantum Genomics (PAR: ALQGC)

Last close As at 21/01/2025

0.17

0.00 (2.35%)

Market capitalisation

EUR6m

Quantum Genomics is a biopharmaceutical company developing firibastat, a brain aminopeptidase A inhibitor for the treatment of hypertension and heart failure. Its mechanism is implicated in the 25% of patients resistant to treatment. The Phase IIb study in hypertension was recently very positive and the Phase IIb in heart failure should start in Q219.

Latest Insights

View More

Healthcare | Flash note

Quantum Genomics — Firibastat misses endpoints in Phase III

Healthcare | Initiation

Quantum Genomics — A fresh take on cardiovascular medicine

Healthcare | Update

Quantum Genomics — Phase IIb QUORUM results

Thematics

thematic

Metals & Mining

Why is gold hitting new highs?

thematic

Investment Companies

Saba Capital campaign – Your vote matters

thematic

Market outlook: What lies ahead in 2025

thematic

Borussia Dortmund – executive interviews

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free